LONDON Oct 3 Britain's AstraZeneca said
it had licensed a potential medicine for inflammatory diseases
to Allergan for an upfront payment of $250 million and
potential additional payments of up to $1.27 billion.
AstraZeneca said the drug developed by its global biologics
research and development arm MedImmune was being testing as a
treatment for moderate-to-severe Crohn's disease and was ready
to start trials for ulcerative colitis.
Amgen Inc, which has been collaborating with
MedImmune on developing the medicine, will receive a third of
all payments and royalties received from Allergan, AstraZeneca
said on Monday.
(Reporting by Paul Sandle; editing by Sarah Young)